Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberWO2001092565 A2
Publication typeApplication
Application numberPCT/EP2001/003973
Publication date6 Dec 2001
Filing date6 Apr 2001
Priority date6 Apr 2000
Also published asDE60126593D1, DE60126593T2, EP1268857A2, EP1268861A2, EP1272670A2, EP1274865A2, EP1274865B1, EP1274866A2, EP1278893A2, EP1360319A2, EP1370685A2, EP2014776A2, EP2014776A3, US7195870, US20030082609, US20030148326, US20030148327, US20030162194, US20040067491, US20040076956, US20050282157, WO2001076451A2, WO2001076451A3, WO2001076451A9, WO2001077164A2, WO2001077164A3, WO2001077164A8, WO2001077375A2, WO2001077375A3, WO2001077375A8, WO2001077376A2, WO2001077376A3, WO2001077376A8, WO2001077377A2, WO2001077377A3, WO2001077377A8, WO2001077378A2, WO2001077378A3, WO2001081622A2, WO2001081622A3, WO2001081622A8, WO2001092565A3, WO2001092565A8
Publication numberPCT/2001/3973, PCT/EP/1/003973, PCT/EP/1/03973, PCT/EP/2001/003973, PCT/EP/2001/03973, PCT/EP1/003973, PCT/EP1/03973, PCT/EP1003973, PCT/EP103973, PCT/EP2001/003973, PCT/EP2001/03973, PCT/EP2001003973, PCT/EP200103973, WO 0192565 A2, WO 0192565A2, WO 2001/092565 A2, WO 2001092565 A2, WO 2001092565A2, WO-A2-0192565, WO-A2-2001092565, WO0192565 A2, WO0192565A2, WO2001/092565A2, WO2001092565 A2, WO2001092565A2
InventorsAlexander Olek, Christian Piepenbrock, Kurt Berlin
ApplicantEpigenomics Ag
Export CitationBiBTeX, EndNote, RefMan
External Links: Patentscope, Espacenet
Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription
WO 2001092565 A2
Abstract
The present invention relates to the chemically modified genomic sequences of genes associated with DNA transcription, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genes associated with DNA transcription which are directed against the sequence, as well as to a method for ascertaining genetic and/or epigenetic parameters of genes associated with DNA transcription.
Description  (OCR text may contain errors)


  



   Diagnosis of diseases associated with DNA transcription
The levels of observation that have been well studied by the methodological developments of recent years in molecular biology, are the genes themselves, the translation of these genes into
RNA, and the resulting proteins. The question of which gene is switched on at which point in the course in of the development of an individual, and how the activation and inhibition of specific genes specific cells and tissues are controlled is correlatable to the degree and character of the methylation of the genes or of the genome. In this respect, pathogenic conditions may manifest themselves in a changed methylation pattern of individual genes or of the genome.



  The present invention relates to nucleic acids, oligonucleotides, PNA-oligomers and to a method for the diagnosis and/or therapy of diseases which have a connection with the genetic and/or epigenetic parameters of genes associated with DNA transcription and, in particular, with the methylation status thereof.



  Prior Art
DNA transcription, the process of using genomic DNA as a template for the synthesis of RNA is a complex process. It requires the interaction of various factors, enzymes and sequences.



  The initiation of DNA transcription requires a complex known as the basal transcription apparatus consisting of RNA polymerase combined with various factors. They form a complex at the startpoint from which transcription proceeds. Examples of such factors include TFIID,   TRF1    and TRF2. This is a major control point for gene expression.



  Transcription factors are often classified according to their DNA binding domain. Members of the same group have sequence variations of a specific motif that confer specificity for individual target sites. Common categories include, steroid receptors, zinc finger motifs, helixturn-helix motifs, helix-loop-helix motifs and leucine zippers.



  The transcription activity is further supplemented by the binding of other components, such as upstream and inducible factors. 



  DNA sequence components of the system include both promoter and enhancer elements.



  Promoter sequences are located in the vicinity of the transcribed region and enhancer elements are located at a distance from the startpoint. These sequences interact with the factors mentioned above to regulate the transcription of RNA.



  Further control may be exerted by the action of insulator elements, specialised chromatin structures that have hypersensitive sites. They are able to block passage of any activating or inactivating effects from enhancers, silencers, or LCRs.



  A further requirement of DNA transcription is that the DNA be accessible. In most cases the initiation of transcription requires that the DNA be free of nucleosomes. Therefore, a transcription factor, or some other nonhistone protein concerned with the particular function of the site, modifies the properties of a short region of DNA so that nucleosomes are excluded.



  Several chromatin modification mechanisms are utilised, including histone acetylation and deacetylation activity.



  A further parameter that regulates genomic transcription is methylation. Methylation of CpG islands in the regulatory regions of genes has been shown to be a common method of transcription regulation. Furthermore, aberrant methylation patterns have been associated with a variety of disease phenotypes.

   For example: -Head and neck cancer: Sanchez-Cespedes M et al.'Gene promoter   hypermethylation    in tumours and serum of head and neck cancer patients'Cancer Res. 2000 Feb. 15; 60 (4): 892-5; -Hodgkin's disease: Garcia JF et al'Loss of pl6 protein expression associated with methylation of the   pl6INK4A    gene is a frequent finding in Hodgkin's disease'Lab invest 1999
Dec; 79 (12): 1453-9; -Gastric cancer: Yanagisawa Y et al.'Methylation of the   hMLHl    promoter in familial gastric cancer with microsatellite instability'Int J Cancer 2000 Jan   1    ; 85 (1): 50-3;   -Prader-Willi/Angelman's    syndrome:

   Zeschnigh et al'Imprinted segments in the human genome: different DNA methylation patterns in the Prader Willi/Angelman syndrome region as determined by the genomic sequencing method'Human Mol. Genetics (1997) (6) 3 pp   387-    395;   -ICF    syndrome: Tuck-Muller et al'CMDNA hypomethylation and unusual chromosome instability in cell lines from ICF syndrome patients'Cytogenet Call Genet 2000; 89 (1-2): 1218;   -Dermatofibroma    : Chen TC et   al'Dermatofibroma    is a clonal proliferative disease'J Cutan
Pathol 2000 Jan; 27 (1): 36-9); -Hypertension: Lee SD et al.'Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension'J clin Invest 1998 Mar   1,      101    (5): 927-34; -Autism:

   Klauck SM et   al.'Molecular    genetic analysis of the FMR-1 gene in a large collection of autistic patients'Human Genet 1997 Aug; 100 (2): 224-9; -Fragile X Syndrome:   Hornstra    IK et al.'High resolution methylation analysis of the FMR1 gene trinucleotide repeat region in fragile X syndrome'Hum Mol Genet 1993 Oct,   2    (10): 1659-65; -Huntigton's disease: Ferluga J et al.'possible organ and age related epigenetic factors in
Huntington's disease and   colorectal carcinoma'Med    hypotheses 1989 May; 29   (1)    ; 51-4;
The proper functioning of the DNA transcription system is essential for the maintenance of cellular functions. Disruptions to the ordered transcription of DNA may impact on a wide variety of disease phenotypes.

   Mutations in sequences coding for and comprising essential components of the DNA transcription system e.   g.    zinc finger proteins and enhancer elements have been implicated in a variety of disorders, including cancer: -Adenosine   deaminase    deficiency: Ariga T'Gene therapy for adenosine   deaminase    (ADA) deficiency: review of the past, the present and the future'Nippon Rinsho 2001 Jan; 59   (1)    : 72-5;  -Cancer: Garte S, Sogawa K'Ah receptor gene polymorphisms and human cancer susceptibility'IARC Sci Publ 1999; (148): 149-57; -Hodgkin's disease:

   Sandvej K, Andresen BS, Zhou XG, Gregersen N, Hamilton-Dutoit S 'Analysis of the   Epstein-Barr    virus (EBV) latent membrane protein   1    (LMP-1) gene and promoter in Hodgkin's disease isolates: selection against EBV variants with mutations in the
LMP-1 promoter   ATF-l/CREB-1    binding site'Mol Pathol 2000 Oct; 53 (5): 280-8; -Ewing's sarcoma family tumors: Aryee DN, Sommergruber W, Muehlbacher K,   Dockhorn-      Dworniczak    B, Zoubek A, Kovar H'Variability in gene expression patterns of Ewing tumor cell lines differing in   EWS-FLI1    fusion type'Lab Invest 2000 Dec; 80 (12):   1833-44    ; -Colon cancer:

   Ishiguro T, Nagawa H, Naito M,   Tsuruo    T Jpn J'Inhibitory effect of ATF3 antisense oligonucleotide on ectopic growth of HT29 human colon cancer cells'Cancer Res 2000 Aug ; 91 (8): 833-6; -Breast cancer: Irminger-Finger   I,    Siegel BD, Leung WC'The functions of breast cancer susceptibility gene 1 (BRCA1) product and its associated proteins'Biol Chem 1999
Feb; 380 (2): 117-28; -Endometrial cancer: Hori M, Takechi K,   Arai    Y, Yomo H, Itabashi M, Shimazaki J, Inagawa S, Hori M'Comparison of macroscopic appearance and estrogen receptor-alpha regulators after gene alteration in human endometrial cancer'Int J Gynecol Cancer 2000
Nov; 10 (6): 469-476; -Wilms'tumor:

   Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H,
Kita K, Hiraoka A, Masaoka T, Nasu K, et   al'WT1    as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia'Blood 1994 Nov
1; 84 (9): 3071-9; -Solid tumors: Kok K, Naylor SL, Buys CH'Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes'Adv Cancer Res 1997 ; 71: 27-92;  -Leukemia; Tanaka T, Kurokawa M, Ueki K, Tanaka K, Imai Y, Mitani K, Okazaki K, Sagata N, Yazaki Y, Shibata Y, Kadowaki T, Hirai H'The extracellular signal-regulated kinase pathway   phosphorylates    AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability'Mol Cell Biol 1996 Jul ; 16 (7): 3967-79;   -Polyglutamine    disorders:

   Nucifora FC Jr, Sasaki M, Peters MF, Huang H, Cooper JK, Yamada M, Takahashi H, Tsuji S, Troncoso J, Dawson VL, Dawson TM, Ross CA'Interference by huntingtin and   atrophin-1    with cbp-mediated transcription leading to cellular toxicity'Science 2001 Mar 23; 291 (5512): 2423-8; -Rheumatoid arthritis:

   Pascual M, Nieto A, Lopez-Nevot MA,   Ramal    L, Mataran L, Caballero A, Alonso A, Martin J, Zanelli E'Rheumatoid arthritis in southern Spain: toward elucidation of a unifying role of the HLA class II region in disease predisposition'Arthritis Rheum 2001 Feb; 44 (2): 307-14; -Neurodegenerative disorders:   Mattila    KM, Axelman K, Rinne JO, Blomberg M, Lehtimaki
T, Laippala P, Roytta M, Viitanen M, Wahlund L, Winblad   B,      Lannfelt    L'Interaction between estrogen receptor 1 and the epsilon4 allele of apolipoprotein E increases the risk of familial
Alzheimer's disease in   women'Neurosci    Lett 2000 Mar 17; 282 (1-2): 45-8; -Myelodysplastic syndrome and acute leukemia:

   Patmasiriwat P, Fraizer G,   Kantarjian    H,
Saunders GF'WT1 and   GATA1    expression in myelodysplastic syndrome and acute leukemia'
Leukemia 1999 Jun;   13    (6): 891-900; -HDR syndrome: Van Esch H, Groenen P, Nesbit MA, Schuffenhauer S, Lichtner P,
Vanderlinden G, Harding B, Beetz R, Bilous RW, Holdaway   I,    Shaw NJ, Fryns JP, Van de
Ven W, Thakker RV, Devriendt   K'GATA3    haplo-insufficiency causes human HDR syndrome'Nature 2000 Jul 27; 406   (6794)    : 419-22;  -Congenital heart disease:

   Pehlivan T, Pober BR, Brueckner M, Garrett S, Slaugh R, Van
Rheeden R, Wilson DB, Watson MS, Hing AV'GATA4 haploinsufficiency in patients with interstitial deletion of chromosome region 8p23.1 and congenital heart disease'Am J Med
 Genet 1999 Mar 19; 83 (3):   201-6 ;     -Angiogenesis and erythropoiesis: Krieg M, Haas R, Brauch H, Acker T, Flamme   I,    Plate
KH'Up-regulation of hypoxia-inducible factors   HIF-1 alpha    and   HIF-2alpha    under   normoxic    conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function Oncogene 2000 Nov 16; 19 (48): 5435-43; -Hypertension:

   Morse JH, Barst RJ, Fotino M, Zhang Y, Flaster E, Fritzler MJ'Primary pulmonary hypertension: immunogenetic response to high-mobility group (HMG) proteins and histone'Clin Exp Immunol 1996 Nov; 106 (2):   389-95    ; -Myocardial infarction: Hegele RA, Huang LS, Herbert PN, Blum CB, Buring JE, Hennekens CH, Breslow JL'Apolipoprotein B-gene DNA polymorphisms associated with myo  cardial infarction.'N Engl J Med    1986 Dec 11; 315 (24): 1509-15; -Early onset pauciarticular chronic arthritis:

   Epplen C, Rumpf H, Albert E, Haas P, Truckenbrodt H, Epplen   JT'Immunoprinting    excludes many potential susceptibility genes as predisposing to early onset pauciarticular juvenile chronic arthritis except HLA class II and TNF'
Eur J   hnmunogenet    1995 Aug; 22 (4): 311-22; -AIDS-related non-Hodgkin lymphomas and Hodgkin lymphomas arising in HIV+ patients:
Carbone A, Gloghini A, Larocca LM, Capello D, Pierconti F, Canzonieri V, Tirelli U, Dalla
Favera R, Gaidano G'Expression profile of   MUM1/IRF4,    BCL-6, and   CD138/syndecan-1    defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas'
Blood 2001 Feb 1; 97 (3):   744-51    ; -Multiple endocrine neoplasia:

   Calender A'Molecular genetics of neuroendocrine tumors'
Digestion 2000 ; 62 Suppl 1: 3-18; -Myelodysplastic syndrome and acute myeloid leukemia: Xie J, Briggs JA, Morris SW,
Olson MO, Kinney MC, Briggs RC'MNDA binds   NPM/B23    and the   NPM-MLF1    chimera generated by the t (3; 5) associated with myelodysplastic syndrome and acute myeloid leuke  mia'Exp Hematol    1997 Oct; 25   (11)    : 1111-7 ;  -Niemann-Pick type C2 disease: Naureckiene S, Sleat DE, Lackland H, Fensom A, Vanier
MT, Wattiaux R, Jadot M, Lobel P'Identification of   HE1    as the second gene of Niemann
Pick C disease'Science 2000 Dec 22; 290 (5500): 2298-301; -Waardenburg syndrome:

   Bondurand N, Pingault V, Goerich DE, Lemort N, Sock E,
Caignec CL, Wegner M, Goossens M'Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome'Hum Mol Genet 2000 Aug 12; 9 (13): 1907-17; -Neurological disorders: Geisbrecht BV, Collins CS, Reuber BE, Gould SJ'Disruption of a   PEX1-PEX6    interaction is the most common cause of the neurologic disorders Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease'Proc Natl Acad Sci
U S A 1998 Jul 21; 95 (15): 8630-5; -Rieger syndrome: Hjalt T, Amendt B, Murray J'PITX2 Regulates Procollagen Lysyl Hydroxylase (PLOD) Gene Expression.

   Implications for the pathology of rieger syndrome'J Cell
Biol 2001 Feb 5; 152 (3): 545-52; -Psoriasis vulgaris: Oka A, Tamiya G, Tomizawa M, Ota M, Katsuyama Y, Makino S,
Shiina T, Yoshitome M,   Iizuka    M, Sasao Y,   Iwashita    K, Kawakubo Y, Sugai J, Ozawa A,
Ohkido M, Kimura M, Bahram S, Inoko H'Association analysis using refined microsatellite markers localizes a susceptibility locus for psoriasis vulgaris within a   111    kb segment telomeric to the HLA-C gene'Hum Mol Genet 1999 Nov; 8 (12): 2165-70; -Developmental disorders: Dattani MT, Robinson   IC'The    molecular basis for developmental disorders of the pituitary gland in man'Clin Genet 2000 May; 57 (5):   337-46 ;    -Tuberculosis:

   Selvaraj P, Narayanan PR, Reetha AM'Association of vitamin D receptor genotypes with the susceptibility to pulmonary tuberculosis in female patients  &  resistance in female contacts'Indian J Med Res 2000   May ; 111    : 172-9; -Werner syndrome: Kitao S, Lindor NM, Shiratori M, Furuichi Y,   Shimamoto    A'Rothmund-thomson syndrome responsible gene, RECQL4: genomic structure and products'Genomics 1999 Nov 1; 61 (3): 268-76;  -Immunological disorders: Puglatti et.   al.'The    genes for MHC class II regulatory factors   RFX1    and RFX2 are located on the short arm of chromosome 19'Genomics 1992
Aug; 13 (4): 1307-10; -Hematological disorders:

   Elbein SC, Teng K, Eddings K, Hargrove D, Scroggin E'Molecular scanning analysis of hepatocyte nuclear factor   lalpha (TCF1)    gene in typical familial type 2 diabetes in African Americans'Metabolism 2000 Feb; 49 (2): 280-4; -Sezary syndrome: Showe LC, Fox FE, Williams D, Au K, Niu Z, Rook AH'Depressed IL12-mediated signal transduction in T cells from patients with Sezary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4'J Immunol 1999 Oct 1; 163 (7): 4073-9; -Viral infection: Yoshida   M'HTLV-1    oncoprotein Tax deregulates transcription of cellular genes through multiple mechanisms'J Cancer Res Clin Oncol 1995; 121 (9-10): 521-8;
The large number of components involved in DNA transcription provide novel targets for therapies and diagnosis for diseases.

   In particular this may be relevant to diseases where current therapies may have unwanted side effects or fail to provide effective treatment. For cancer patients such methods constitute a considerable advantage over conventional methods such as chemotherapy, which with their massive side effects, sometimes result in unacceptable morbidity or lead up to the death of the patient. In practice, the unwanted side effects associated with cancer therapies frequently limit the treatment which could help a patient.



  A global analysis of the status of DNA transcription mechanisms would provide a basis for the development of appropriate and specific therapies for diseases associated with DNA replication. The current state of the art is such that the analysis may be carried out in a gene specific manner based on the results of gene expression, e. g. DNA micro array analysis of mRNA expression or proteomic analysis. The next step would then be to look at the causal factors involved at earlier stages in the regulatory mechanisms controlling DNA transcription.



  DNA methylation provides a novel level of information at which to analyse the genome. 



  5-methylcytosine is the most frequent covalent base modification in the DNA of eukaryotic cells. It plays a role, for example, in the regulation of the transcription, in genetic imprinting, and in tumorigenesis. Therefore, the identification of   5-methylcytosine    as a component of genetic information is of considerable interest. However, 5-methylcytosine positions cannot be identified by sequencing since 5-methylcytosine has the same base pairing behavior as cytosine. Moreover, the epigenetic information carried by 5-methylcytosine is completely lost during PCR amplification.



  A relatively new and currently the most frequently used method for analyzing DNA for 5  methylcytosine    is based upon the specific reaction of bisulfite with cytosine which, upon subsequent alkaline hydrolysis, is converted to uracil which corresponds to thymidine in its base pairing behavior. However, 5-methylcytosine remains unmodified under these conditions.



  Consequently, the original DNA is converted in such a manner that methylcytosine, which originally could not be distinguished from cytosine by its hybridization behavior, can now be detected as the only remaining cytosine   using"normal"molecular    biological techniques, for example, by amplification and hybridization or sequencing. All of these techniques are based on base pairing which can now be fully exploited. In terms of sensitivity, the prior art is defined by a method which encloses the DNA to be analyzed in an agarose matrix, thus preventing the diffusion and renaturation of the DNA (bisulfite only reacts with single-stranded
DNA), and which replaces all precipitation and purification steps with fast dialysis   (Olek    A,
Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis.

   Nucleic Acids Res. 1996 Dec 15; 24 (24): 5064-6). Using this method, it is possible to analyze individual cells, which illustrates the potential of the method. However, currently only individual regions of a length of up to approximately 3000 base pairs are analyzed, a global analysis of cells for thousands of possible methylation events is not possible. However, this method cannot reliably analyze very small fragments from small sample quantities either. These are lost through the matrix in spite of the diffusion protection.



  An overview of the further known methods of detecting 5-methylcytosine may be gathered from the following review article: Rein, T., DePamphilis, M. L., Zorbas, H., Nucleic Acids
Res. 1998,26,2255. 



  To date, barring few exceptions (e. g., Zeschnigk M, Lich C,   Buiting    K,   Doerfler    W,
Horsthemke B. A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus. Eur J Hum Genet. 1997
Mar-Apr;   5    (2): 94-8) the bisulfite technique is only used in research. Always, however, short, specific fragments of a known gene are amplified subsequent to a bisulfite treatment and either completely sequenced   (Olek    A, Walter J. The pre-implantation ontogeny of the   H19    methylation imprint. Nat Genet. 1997 Nov;   17    (3): 275-6) or individual cytosine positions are detected by a primer extension reaction (Gonzalgo   ML,    Jones PA.

   Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res. 1997 Jun 15; 25 (12): 252.9-31, WO 95/00669) or by enzymatic digestion (Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997 Jun 15; 25 (12): 2532-4). In addition, detection by hybridization has also been described   (Olek    et al., WO   99/28498).   



  Further publications dealing with the use of the bisulfite technique for methylation detection in individual genes are: Grigg G, Clark S. Sequencing 5-methylcytosine residues in genomic
DNA. Bioessays. 1994 Jun;   16    (6): 431-6,431; Zeschnigk M, Schmitz B,   Dittrich B, Buiting K,   
Horsthemke B, Doerfler W. Imprinted segments in the human genome : different DNA methylation patterns in the Prader-Willi/Angelman syndrome region as determined by the genomic sequencing method. Hum Mol Genet. 1997 Mar; 6 (3): 387-95;   Feil    R, Charlton J, Bird AP,
Walter J, Reik W. Methylation analysis on individual chromosomes: improved protocol for bisulphite genomic sequencing. Nucleic Acids Res. 1994 Feb 25; 22 (4): 695-6; Martin V,
Ribieras S, Song-Wang X, Rio MC, Dante R.

   Genomic sequencing indicates a correlation between DNA hypomethylation in the 5'region of the pS2 gene and its expression in human breast cancer cell lines. Gene.   1995    May 19; 157 (1-2): 261-4; WO 97/46705, WO 95/15373 and WO 97/45560.



  An overview of the Prior Art in oligomer array manufacturing can be gathered from a special edition of Nature Genetics (Nature Genetics Supplement, Volume 21, January 1999), published in January 1999, and from the literature cited therein.



  Fluorescently labeled probes are often used for the scanning of immobilized DNA arrays. The simple attachment of Cy3 and   Cy5    dyes to the 5'-OH of the specific probe are particularly suitable for fluorescence labels. The detection of the fluorescence of the hybridized probes may be carried out, for example via a confocal microscope. Cy3 and   Cy5    dyes, besides many others, are commercially available.



  Matrix Assisted Laser Desorption Ionization Mass Spectrometry   (MALDI-TOF)    is a very efficient development for the analysis of biomolecules (Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem.



  1988 Oct 15; 60 (20): 2299-301). An analyte is embedded in a light-absorbing matrix. The matrix is evaporated by a short laser pulse thus transporting the analyte molecule into the vapor phase in an unfragmented manner. The analyte is ionized by collisions with matrix molecules.



  An applied voltage accelerates the ions into a field-free flight tube. Due to their different masses, the ions are accelerated at different rates. Smaller ions reach the detector sooner than bigger ones.



  MALDI-TOF spectrometry is excellently suited to the analysis of peptides and proteins. The analysis of nucleic acids is somewhat more difficult (Gut I G, Beck S. DNA and Matrix Assisted Laser Desorption Ionization Mass Spectrometry. Current Innovations and Future
Trends. 1995,1; 350-57). The sensitivity to nucleic acids is approximately 100 times worse than to peptides and decreases disproportionally with increasing fragment size. For nucleic acids having a multiply negatively charged backbone, the ionization process via the matrix is considerably less efficient. In MALDI-TOF spectrometry, the selection of the matrix plays an eminently important role. For the desorption of peptides, several very efficient matrixes have been found which produce a very fine crystallization. There are now several responsive matrixes for DNA, however, the difference in sensitivity has not been reduced.

   The difference in sensitivity can be reduced by chemically modifying the DNA in such a manner that it becomes more similar to a peptide. Phosphorothioate nucleic acids in which the usual phosphates of the backbone are substituted with thiophosphates can be converted into a chargeneutral DNA using simple alkylation chemistry (Gut IG, Beck S. A procedure for selective
DNA alkylation and detection by mass spectrometry. Nucleic Acids Res. 1995 Apr 25; 23 (8): 1367-73). The coupling of a charge tag to this modified DNA results in an increase in sensitivity to the same level as that found for peptides. A further advantage of charge tagging is the increased stability of the analysis against impurities which make the detection of unmodified substrates considerably more difficult. 



  Genomic DNA is obtained from DNA of cell, tissue or other test samples using standard methods. This standard methodology is found in references such as Fritsch and Maniatis eds.,
Molecular Cloning: A Laboratory Manual, 1989.



  Description
The object of the present invention is to provide the chemically modified DNA of genes associated with DNA transcription, as well as oligonucleotides   and/or    PNA-oligomers for detecting cytosine methylations, as well as a method which is particularly suitable for the diagnosis   and/or    therapy of genetic and epigenetic parameters of genes associated with DNA transcription. The present invention is based on the discovery that genetic and epigenetic parameters and, in particular, the cytosine methylation pattern of genes associated with DNA transcription are particularly suitable for the diagnosis and/or therapy of diseases associated with DNA transcription.



  This objective is achieved according to the present invention using a nucleic acid containing a sequence of at least 18 bases in length of the chemically pretreated DNA of genes associated with DNA transcription according to one of Seq. ID No.   l    through Seq. ID No. 346 and sequences complementary thereto and/or a chemically pretreated DNA of genes according to the sequences of genes according to table   1    and sequences complementary thereto. In the table, after the listed gene designations, the respective data bank numbers (accession numbers) are specified which define the appertaining gene sequences as unique. GenBank was used as the underlying data bank, which is located at the National Institute of Health at internet address http://www. ncbi. nlm. nih. gov.



  The chemically modified nucleic acid could heretofore not be connected with the ascertainment of genetic and epigenetic parameters.



  The object of the present invention is further achieved by an oligonucleotide or oligomer for detecting the cytosine methylation state in chemically pretreated DNA, containing at least one base sequence having a length of at least 13 nucleotides which hybridizes to a chemically pretreated DNA of genes associated with DNA transcription according to Seq. ID No.   l    through Seq. ID No. 346 and sequences complementary thereto   and/or    a chemically pretreated 
DNA of genes according to the sequences of genes according to table   1    and sequences complementary thereto. The oligomer probes according to the present invention constitute important and effective tools which, for the first time, make it possible to ascertain the genetic and epigenetic parameters of genes associated with DNA transcription.

   The base sequence of the oligomers preferably contain at least one CpG dinucleotide. The probes may also exist in the form   of a PNA (peptide    nucleic acid) which has particularly preferred pairing properties. Particularly preferred are oligonucleotides according to the present invention in which the cytosine of the CpG dinucleotide is the 5th-9th nucleotide from the 5'-end of the 13-mer; in the case of PNA-oligomers, it is preferred for the cytosine of the CpG dinucleotide to be the   4th-    6th nucleotide from the 5'-end of the 9-mer.



  The oligomers according to the present invention are normally used in so called"sets"which contain at least one oligomer for each of the CpG dinucleotides of the sequences of Seq. ID
No.   l    through Seq. ID No.   346    and sequences complementary thereto and/or a chemically pretreated DNA of genes according to the sequences of genes according to table 1 and sequences complementary thereto. Preferred is a set which contains at least one oligomer for each of the
CpG dinucleotides from one of Seq. ID No.   l    through Seq. ID No. 346 and sequences complementary thereto   and/or    a chemically pretreated DNA of genes according to the sequences of genes according to table 1 and sequences complementary thereto.



  Moreover, the present invention makes available a set of at least two oligonucleotides which can be used as so-called"primer oligonucleotides"for amplifying DNA sequences of one of
Seq. ID No.   l    through Seq. ID No. 346 and sequences complementary thereto   and/or    a chemically pretreated DNA of genes according to the sequences of genes according to table 1 and sequences complementary thereto, or segments thereof.



  In the case of the sets of oligonucleotides according to the present invention, it is preferred that at least one oligonucleotide is bound to a solid phase.



  The present invention moreover relates to a set of at least 10 n (oligonucleotides   and/or    PNAoligomers) used for detecting the cytosine methylation state in chemically pretreated genomic
DNA (Seq. ID No.   l    through Seq. ID No. 346 and sequences complementary thereto   and/or    a chemically pretreated DNA of genes according to the sequences of genes according to table   1    and sequences complementary thereto). These probes enable diagnosis   and/or    therapy of genetic and epigenetic parameters of genes associated with DNA transcription. The set of oligomers may also be used for detecting single nucleotide polymorphisms (SNPs) in the chemically pretreated DNA of genes associated with DNA transcription according to one of Seq.

   ID
No.   l    through Seq. ID No. 346 and sequences complementary thereto   and/or    a chemically pretreated DNA of genes according to the sequences of genes according to table   1    and sequences complementary thereto.



  According to the present invention, it is preferred that an arrangement of different oligonucleotides   and/or    PNA-oligomers (a so-called"array") made available by the present invention is present in a manner that it is likewise bound to a solid phase. This array of different oligonucleotide-and/or PNA-oligomer sequences can be characterized in that it is arranged on the solid phase in the form of a rectangular or hexagonal lattice. The solid phase surface is   pref-    erably composed of silicon, glass, polystyrene, aluminium, steel, iron, copper, nickel, silver, or gold. However, nitrocellulose as well as plastics such as nylon which can exist in the form of pellets or also as resin matrices are possible as well.



  Therefore, a further subject matter of the present invention is a method for manufacturing an array fixed to a carrier material for analysis in connection with diseases associated with DNA transcription in which method at least one oligomer according to the present invention is coupled to a solid phase. Methods for manufacturing such arrays are known, for example, from
US Patent 5,744,305 by means of solid-phase chemistry and photolabile protecting groups.



  A further subject matter of the present invention relates to a DNA chip for the analysis of diseases associated with DNA transcription which contains at least one nucleic acid according to the present invention. DNA chips are known, for example, for US Patent 5,837,832.



  Moreover, a subject matter of the present invention is a kit which may be composed, for example, of a bisulfite-containing reagent, a set of primer oligonucleotides containing at least two oligonucleotides whose sequences in each case correspond or are complementary to an 18 base long segment of the base sequences specified in the appendix (Seq. ID No.   l    through Seq.



  ID No. 346 and sequences complementary thereto and/or a chemically pretreated DNA of genes according to the sequences of genes according to table 1 and sequences complementary thereto), oligonucleotides and/or PNA-oligomers as well as instructions for carrying out and evaluating the described method. However, a kit along the lines of the present invention can also contain only part of the aforementioned components.



  The present invention also makes available a method for ascertaining genetic and/or epigenetic parameters of genes associated with the cycle cell by analyzing cytosine methylations and single nucleotide polymorphisms, including the following steps:
In the first step of the method, a genomic DNA sample is chemically treated in such a manner that cytosine bases which are   unmethylated    at the 5'-position are converted to uracil, thymine, or another base which is dissimilar to cytosine in terms of hybridization behavior. This will be understood as'chemical   pretreatment'hereinafter.   



  The genomic DNA to be analyzed is preferably obtained form usual sources of DNA such as cells or cell components, for example, cell lines, biopsies, blood, sputum, stool, urine, cerebral-spinal fluid, tissue embedded in paraffin such as tissue from eyes, intestine, kidney, brain, heart, prostate, lung, breast or liver, histologic object slides, or combinations thereof.



  The above described treatment of genomic DNA is preferably carried out with bisulfite (hydrogen sulfite, disulfite) and subsequent alkaline hydrolysis which results in a conversion of non-methylated cytosine nucleobases to uracil or to another base which is dissimilar to cytosine in terms of base pairing behavior.



  Fragments of the chemically pretreated DNA are amplified, using sets of primer oligonucleotides according to the present invention, and a, preferably heat-stable polymerase. Because of statistical and practical considerations, preferably more than ten different fragments having a length of 100-2000 base pairs are amplified. The amplification of several DNA segments can be carried out simultaneously in one and the same reaction vessel. Usually, the amplification is carried out by means of a polymerase chain reaction (PCR).



  In a preferred embodiment of the method, the set of primer oligonucleotides includes at least two olignonucleotides whose sequences are each reverse complementary or identical to an at least 18 base-pair long segment of the base sequences specified in the appendix (Seq. ID No.   l    through Seq. ID No. 346 and sequences complementary thereto and/or a chemically pretreated
DNA of genes according to the sequences of genes according to table 1 and sequences complementary thereto). The primer oligonucleotides are preferably characterized in that they do not contain any CpG dinucleotides.



  According to the present invention, it is preferred that at least one primer oligonucleotide is bonded to a solid phase during amplification. The different oligonucleotide and/or PNAoligomer sequences can be arranged on a plane solid phase in the form of a rectangular or hexagonal lattice, the solid phase surface preferably being composed of silicon, glass, polystyrene, aluminium, steel, iron, copper, nickel, silver, or gold, it being possible for other materials such as nitrocellulose or plastics to be used as well.



  The fragments obtained by means of the amplification can carry a directly or indirectly detectable label. Preferred are labels in the form of fluorescence labels, radionuclides, or detachable molecule fragments having a typical mass which can be detected in a mass spectrometer, it being preferred that the fragments that are produced have a single positive or negative net charge for better detectability in the mass spectrometer. The detection may be carried out and visualized by means of matrix assisted laser desorption/ionization mass spectrometry (MALDI) or using electron spray mass spectrometry (ESI).



  The amplificates obtained in the second step of the method are subsequently hybridized to an array or a set of oligonucleotides   and/or    PNA probes. In this context, the hybridization takes place in the manner described in the following. The set of probes used during the hybridization is preferably composed of at least 10 oligonucleotides or PNA-oligomers. In the process, the amplificates serve as probes which hybridize to oligonucleotides previously bonded to a solid phase. The non-hybridized fragments are subsequently removed. Said oligonucleotides contain at least one base sequence having a length of 13 nucleotides which is reverse complementary or identical to a segment of the base sequences specified in the appendix, the segment containing at least one CpG dinucleotide.

   The cytosine of the CpG dinucleotide is the   5th    to 9th nucleotide from the 5'-end of the 13-mer. One oligonucleotide exists for each
CpG dinucleotide. Said PNA-oligomers contain at least one base sequence having a length of 9 nucleotides which is reverse complementary or identical to a segment of the base sequences specified in the appendix, the segment containing at least one CpG dinucleotide. The cytosine of the CpG dinucleotide is the   4th    to 6th nucleotide seen from the 5'-end of the 9-mer. One oligonucleotide exists for each CpG dinucleotide.



  In the fourth step of the method, the non-hybridized amplificates are removed.



  In the final step of the method, the hybridized amplificates are detected. In this context, it is preferred that labels attached to the amplificates are identifiable at each position of the solid phase at which an oligonucleotide sequence is located.



  According to the present invention, it is preferred that the labels of the amplificates are fluorescence labels, radionuclides, or detachable molecule fragments having a typical mass which can be detected in a mass spectrometer. The mass spectrometer is preferred for the detection of the amplificates, fragments of the amplificates or of probes which are complementary to the amplificates, it being possible for the detection to be carried out and visualized by means of matrix assisted laser desorption/ionization mass spectrometry (MALDI) or using electron spray mass spectrometry (ESI).



  The produced fragments may have a single positive or negative net charge for better detectability in the mass spectrometer. The aforementioned method is preferably used for ascertaining genetic and/or epigenetic parameters of genes associated with DNA transcription.



  The oligomers according to the present invention or arrays thereof as well as a kit according to the present invention are intended to be used for the diagnosis and/or therapy of diseases associated with DNA transcription by analyzing methylation patterns of genes associated with
DNA transcription. According to the present invention, the method is preferably used for the diagnosis and/or therapy of important genetic and/or epigenetic parameters within genes associated with DNA transcription.



  The method according to the present invention is used, for example, for the diagnosis   and/or    therapy of diseases. 



  The nucleic acids according to the present invention of Seq. ID No.   l    through Seq.   ID No.    346 and sequences complementary thereto and/or a chemically pretreated DNA of genes according to the sequences of genes according to table   1    and sequences complementary thereto can be used for the diagnosis and/or therapy of genetic and/or epigenetic parameters of genes associated with DNA transcription.



  The present invention moreover relates to a method for manufacturing a diagnostic agent and/or therapeutic agent for the diagnosis and/or therapy of diseases associated with DNA transcription by analyzing methylation patterns of genes associated with DNA transcription, the diagnostic agent and/or therapeutic agent being characterized in that at least one nucleic acid according to the present invention is used for manufacturing it, possibly together with suitable additives and auxiliary agents.



  A further subject matter of the present invention relates to a diagnostic agent   and/or    therapeutic agent for diseases associated with DNA transcription by analyzing methylation patterns of genes associated with DNA transcription, the diagnostic agent   and/or    therapeutic agent containing at least one nucleic acid according to the present invention, possibly together with suitable additives and auxiliary agents.



  The present invention moreover relates to the diagnosis   and/or    prognosis of events which are disadvantageous to patients or individuals in which important genetic   and/or    epigenetic parameters within genes associated with DNA transcription said parameters obtained by means of the present invention may be compared to another set of genetic   and/or    epigenetic parameters, the differences serving as the basis for a diagnosis   and/or    prognosis of events which are disadvantageous to patients or individuals.



  In the context of the present invention the   term"hybridization"is    to be understood as a bond of an oligonucleotide to a completely complementary sequence along the lines of the Watson
Crick base pairings in the sample DNA, forming a duplex structure. To be understood by "stringent hybridization conditions"are those conditions in which a hybridization is carried out at   60 C    in 2.5 x SSC buffer, followed by several washing steps at   37 C    in a low buffer concentration, and remains stable. 



  The   term"functional    variants"denotes all DNA sequences which are complementary to a
DNA sequence, and which hybridize to the reference sequence under stringent conditions and have an activity similar to the corresponding polypeptide according to the present invention.



  In the context of the present invention,"genetic parameters"are mutations and polymorphisms of genes associated with DNA transcription and sequences further required for their regulation. To be designated as mutations are, in particular, insertions, deletions, point mutations, inversions and polymorphisms and, particularly preferred, SNPs (single nucleotide polymorphisms).



  In the context of the present invention,"epigenetic   parameters"are,    in particular, cytosine methylations and further chemical modifications of DNA bases of genes associated with DNA transcription and sequences further required for their regulation. Further epigenetic parameters include, for example, the acetylation of histones which, however, cannot be directly analyzed using the described method but which, in turn, correlates with the DNA methylation.



  In the following, the present invention will be explained in greater detail on the basis of the sequences and examples with respect to the accompanying figure without being limited thereto.



  Figure 1
Figure   1    shows the hybridisation of fluorescent labelled amplificates to a surface bound olignonucleotide. Sample I being from a pilocytic astrocytoma tumor sample and sample II being form an oligodenrogliome grade II tumor sample. Flourescence at a spot shows hybridisation of the amplificate to the olignonucleotide. Hybridisation to a CG olgnonucleotide denotes methylation at the cytosine position being analysed, gybridisation to a TG olignonucleotide denates no methylation at the cytosine position being analysed.



  Seq. ID No. 1 through Seq. ID No. 346
Sequences having odd sequence numbers (e. g., Seq. ID No. 1,3,5,...) exhibit in each case sequences of the chemically pretreated genomic DNAs of different genes associated with
DNA transcription. Sequences having even sequence numbers (e. g., Seq. ID No. 2,4,6,...) exhibit in each case the sequences of the chemically pretreated genomic DNAs of genes asso ciated with DNA transcription which are complementary to the preceeding sequences (e. g., the complementary sequence to Seq.   ID    No.   l    is Seq. ID No. 2, the complementary sequence to
Seq. ID No. 3 is Seq. ID No. 4, etc.)
Seq. ID No. 347 through Seq. ID No. 350
Seq. ID No. 347 through Seq. ID No. 350 show sequences of oligonucleotides used in Example 1.



  The following example relates to a fragment of a gene associated with DNA transcription, in this case, CFOS in which a specific CG-position is analyzed for its methylation status.



  Example   l    : Methylation analysis in the gene CFOS associated with DNA transcription.



  The following example relates to a fragment of the gene CFOS in which a specific CGposition is to be analyzed for methylation.



  In the first step, a genomic sequence is treated using bisulfite (hydrogen sulfite, disulfite) in such a manner that all cytosines which are not methylated at the 5-position of the base are modified in such a manner that a different base is substituted with regard to the base pairing behavior while the cytosines methylated at the 5-position remain unchanged.



  If bisulfite solution is used for the reaction, then an addition takes place at the non-methylated cytosine bases. Moreover, a denaturating reagent or solvent as well as a radical interceptor must be present. A subsequent alkaline hydrolysis then gives rise to the conversion of nonmethylated cytosine nucleobases to uracil. The chemically converted DNA (sequence ID 345) is then used for the detection of methylated cytosines. In the second method step, the treated
DNA sample is diluted with water or an aqueous solution. Preferably, the DNA is subsequently desulfonated (10-30 min,   90-100  C)    at an alkaline pH value. In the third step of the method, the DNA sample is amplified in a polymerase chain reaction, preferably using a heatresistant DNA polymerase. In the present case, cytosines of the gene CFOS are analyzed.

   To this end, a defined fragment having a length of 951 bp is amplified with the specific primer oligonucleotides   TTTTGAGTTTTAGAATTGTT    (Sequence ID No. 347) and
AAAAACCCCCTACTCATCTA (Sequence ID No. 348). This amplificate serves as a sample which hybridizes to an oligonucleotide previously bonded to a solid phase, forming a duplex structure, for example AAAACATTCGCACCTAAT (Sequence ID No. 349), the cytosine to be detected being located at position 105. of the amplificate. The detection of the hybridization product is based on Cy3 and Cy5   fluorescently    labeled primer oligonucleotides which have been used for the amplification. A hybridization reaction of the amplified DNA with the oligonucleotide takes place only if a methylated cytosine was present at this location in the bisulfite-treated DNA.

   Thus, the methylation status of the specific cytosine to be analyzed is inferred from the hybridization product.



  In order to verify the methylation status of the position, a sample of the amplificate is further hybridized to another oligonucleotide previously bonded to a solid phase. Said oligonucleotide is identical to the oligonucleotide previously used to analyze the methylation status of the sample, with the exception of the position in question. At the position to be analysed said oligonucleotide comprises a thymine base as opposed to a cytosine base i. e
AAAACATTCACACCTAAT (Sequence ID No. 350). Therefore, the hybridisation reaction only takes place if an   unmethylated    cytosine was present at the position to be analysed. The procedure was carried out on cell samples from 2 patients, sample I being from a pilocytic astrocytoma tumor sample and sample II being from an oligodenrogliome grade II tumor sample.



  From the results (Figure 1) it can be seen that Sample I contained both methylated and unmethylated cells and sample II was unmethylated.



  Example 2: Diagnosis of diseases associated with DNA transcription
In order to relate the methylation patterns to one of the diseases associated with DNA transcription, it is initially required to analyze the DNA methylation patterns of a group of diseased and of a group of healthy patients. These analyses are carried out, for example, analogously to Example 1. The results obtained in this manner are stored in a database and the CpG dinucleotides which are methylated differently between the two groups are identified. This can be carried out by determining individual CpG methylation rates as can be done, for example, in a relatively imprecise manner, by sequencing or else, in a very precise manner, by a methylation-sensitive"primer extension reaction".

   It is also possible for the entire methylation status to be analyzed simultaneously, and for the patterns to be compared, for example, by clustering analyses which can be carried out, for example, by a computer. 
Subsequently, it is possible to allocate the examined patients to a specific therapy group and to treat these patients selectively with an individualized therapy.



  Example 2 can be carried out, for example, for the following diseases:
Adenosine deaminase deficiency, Viral infection, Retroviral infection, Sezary syndrome, Hematological disorders, Immunological disorders, Werner syndrome, Tuberculosis, Developmental disorders, Psoriasis, Rieger syndrome, Neurological disorders, Neurodegenerative disorders, Waardenburg syndrome, Niemann-Pick disease, Myelodysplastic syndrome, Myocardial infarction, Hypertension, Angiogenesis, Erythropoiesis, Congenital heart disease,
HDR syndrome, Myelodysplastic syndrome, Arthiritis,   Polyglutamine    disorders, solid tumors and cancer
Table   1   
Listing of particularly preferred genes of the present invention associated with DNA tran scription
EMI22.1     


<tb> Gene <SEP> Database <SEP> Entry <SEP> No. <SEP> (Genbank <SEP> a
<tb>  <SEP> htp <SEP> :

   <SEP> llwww. <SEP> ncbi. <SEP> nlmnih. <SEP> gov)
<tb>  <SEP> ELF1 <SEP> M82882
<tb>  <SEP> ETV3 <SEP> 16464
<tb>  <SEP> ETV4 <SEP> D12765
<tb>  <SEP> AF2C2 <SEP> Y09321
<tb>  <SEP> TCF9 <SEP> M29204
<tb>  <SEP> ZNF121 <SEP> M99593
<tb>  <SEP> NF131 <SEP> U09410
<tb>  <SEP> NF139 <SEP> U09848
<tb>  <SEP> ZNF154 <SEP> U20648
<tb>  <SEP> ZNF169 <SEP> U28322
<tb>  <SEP> F2 <SEP> X60152
<tb>  <SEP> ZNF204 <SEP> AF033199
<tb>  <SEP> F206 <SEP> AA206569
<tb>  <SEP> ZNF3 <SEP> X78926
<tb>  
EMI23.1     


<tb> Gene <SEP> Database <SEP> Entry <SEP> No. <SEP> (Genbank <SEP> at
<tb>  <SEP> http:

  //www.ncbi.nlm.nih.gov)
<tb>  <SEP> ZNF37A <SEP> X69115
<tb>  <SEP> ZNF44 <SEP> X16281
<tb>  <SEP> ZNF8 <SEP> M29581
<tb>  <SEP> ZK1 <SEP> NM¯05815
<tb>  <SEP> ADA <SEP> NM¯000022
<tb>  <SEP> ATBF1 <SEP> NM¯06885
<tb>  <SEP> ATF3 <SEP> NM¯001674
<tb>  <SEP> ZNF255 <SEP> NM¯005774
<tb> CBFB <SEP> NM¯001755
<tb> CEBPD <SEP> NM¯005195
<tb> CTPS <SEP> NM¯001905
<tb>  <SEP> DCTD <SEP> NM¯001921
<tb>  <SEP> DR1 <SEP> NM¯001938
<tb>  <SEP> 3ELF3 <SEP> NM¯004433
<tb>  <SEP> ELK4 <SEP> NM¯021795
<tb>  <SEP> ETV5 <SEP> NM¯004454
<tb>  <SEP> KLF4 <SEP> NM¯004235
<tb>  <SEP> FOXO1A <SEP> NM¯002015
<tb>  <SEP> FLI1 <SEP> NM¯002017
<tb>  <SEP> HHEX <SEP> NM¯001529
<tb>  <SEP> HIVEP1 <SEP> NM¯002114
<tb>  <SEP> HMG2 <SEP> NM¯002129
<tb>  <SEP> ID1 <SEP> NM¯002165
<tb>  <SEP> ID3 <SEP> NM¯002167
<tb>  <SEP> LAF4 <SEP> NM¯002285
<tb>  <SEP> ZNFN <SEP> 1A1 <SEP> NM¯006060
<tb>  <SEP> LYL1 <SEP> 

  NM¯005583
<tb>  <SEP> MAFG <SEP> NM¯002359
<tb>  <SEP> MAZ <SEP> NM¯002383
<tb> ODC1 <SEP> NM¯002539
<tb>  
EMI24.1     


<tb> Gene <SEP> Database <SEP> Entry <SEP> No. <SEP> (Genbank <SEP> a
<tb>  <SEP> http://ww.ncbi.nlm.nih.gov)
<tb>  <SEP> BX3 <SEP> NM¯006195
<tb>  <SEP> POU2AF1NM006235
<tb>  <SEP> POU2F2 <SEP> NM¯002698
<tb>  <SEP> POU3F1 <SEP> NM¯002699
<tb>  <SEP> PROP1 <SEP> NM¯006261
<tb>  <SEP> RARG <SEP> NM¯00966
<tb>  <SEP> RECQL <SEP> NM¯002907
<tb>  <SEP> RXRA <SEP> NM¯002957
<tb> SP100 <SEP> NM¯003113
<tb>  <SEP> ZEP93 <SEP> NM¯004234
<tb>  <SEP> MKRN3 <SEP> NM¯005664
<tb>  <SEP> ZNF133NM003434
<tb>  <SEP> NF157 <SEP> NM¯003446
<tb>  <SEP> NF173 <SEP> NM¯003449
<tb>  <SEP> NF189 <SEP> NM¯003452
<tb>  <SEP> NF207 <SEP> NM¯003457
<tb>  <SEP> NF262 <SEP> NM¯005095
<tb>  <SEP> NM¯264 <SEP> NM¯003417
<tb>  <SEP> NF74 <SEP> NM¯003426
<tb>  <SEP> NF91 <SEP> NM¯003430
<tb>  

  <SEP> OU3F2 <SEP> NM¯005604
<tb>  <SEP> NF84 <SEP> NM¯003428
<tb>  <SEP> ERV3
<tb>  <SEP> TCF8
<tb>

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
WO1999028498A2 *27 Nov 199810 Jun 1999Epigenomics GmbhMethod for producing complex dna methylation fingerprints
WO1999029898A2 *4 Dec 199817 Jun 1999MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.Method for identifying nucleic acids by means of matrix-assisted laser desorption/ionisation mass spectrometry
WO2001068912A2 *15 Mar 200120 Sep 2001Epigenomics AgDiagnosis of diseases associated with tumor suppressor genes and oncogenes
WO2001077375A2 *6 Apr 200118 Oct 2001Epigenomics AgDiagnosis of diseases associated with gene regulation
WO2001077377A2 *6 Apr 200118 Oct 2001Epigenomics AgDiagnosis of diseases associated with dna replication by assessing dna methylation
US5744305 *6 Jun 199528 Apr 1998Affymetrix, Inc.Arrays of materials attached to a substrate
Non-Patent Citations
Reference
1 *BRUNK BP ET AL.: "Regulated demethylation of the myoD distal enhancer during skeletal myogenesis." DEVELOPMENTAL BIOLOGY, vol. 177, no. 2, 1996, pages 490-503, XP001026536 & DATABASE GENBANK [Online] NCBI; 28 December 1996 (1996-12-28) BRUNK BP ET AL.: "myoD (distal enhancer region)" retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV/ Database accession no. S82831
2 *DATABASE EMBL [Online] EBI; 10 October 1995 (1995-10-10) OGURA T.: "NAD+ ADP-ribosyltransferase; PADPRP-I gene; promoter" retrieved from HTTP://WWW.EBI.AC.UK/CGI-BIN/EMBLFETCH Database accession no. X16674 XP002187359 -& OGURA T ET AL.: "Characterization of a putative promoter region of the human poly(ADP-ribose) polymerase gene: structural similarity to that of the DNA polymerase beta gene." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 167, no. 2, 16 March 1990 (1990-03-16), pages 701-710, XP002187357
3 *DATABASE EMBL [Online] EBI; 11 October 1999 (1999-10-11) BIRREN B ET AL.: "Homo sapiens clone RP11-15H13" retrieved from HTTP://WWW.EBI.AC.UK/CGI-BIN/EMBLFETCH Database accession no. AC011651 XP002187361
4 *DATABASE EMBL [Online] EBI; 2 July 1999 (1999-07-02) HERZOG ET AL.: "human poly(ADP-ribose) polymerase gene, 5' end." retrieved from HTTP://WWW.EBI.AC.UK/CGI-BIN/EMBLFETCH Database accession no. M60436 XP002187360
5 *DATABASE GENBANK [Online] NCBI; 7 August 1998 (1998-08-07) CHEN B ET AL.: "Homo sapiens myogenic determining factor 3 (MYOD1) gene" retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV/ Database accession no. AF027148 XP002187358
6 *See also references of EP1268861A2
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
WO2001077377A2 *6 Apr 200118 Oct 2001Epigenomics AgDiagnosis of diseases associated with dna replication by assessing dna methylation
WO2001077377A3 *6 Apr 200111 Jul 2002Epigenomics AgDiagnosis of diseases associated with dna replication by assessing dna methylation
WO2004005476A3 *3 Jul 200321 May 2004Coley Pharm Group IncNucleic acid compositions for stimulating immune responses
EP1554407B1 *1 Oct 200329 Jul 2009Epigenomics AGMethod for the treatment of breast cell proliferative disorders
EP1561821A213 Dec 200410 Aug 2005Epigenomics AGPrognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
EP1676927A2 *2 Jul 20015 Jul 2006Epigenomics AGDiagnosis of diseases associated with development by means of assessing their methylation status
EP1676927A3 *2 Jul 20016 Dec 2006Epigenomics AGDiagnosis of diseases associated with development by means of assessing their methylation status
EP2157191A3 *1 Oct 20039 Jun 2010Epigenomics AGMethod and nucleic acids for the improved treatment of breast cell proliferative disorders
US681840411 Apr 200216 Nov 2004Exact Sciences CorporationMethods for detecting hypermethylated nucleic acid in heterogeneous biological samples
US71958706 Apr 200127 Mar 2007Epigenomics AgDiagnosis of diseases associated with gene regulation
US738180813 Jun 20023 Jun 2008Epigenomics AgMethod and nucleic acids for the differentiation of prostate tumors
US74320507 Oct 20027 Oct 2008Case Western Reserve UniversityMethods and compositions for detecting colon cancers
US78078033 Jul 20035 Oct 2010Coley Pharmaceutical Group, Inc.Nucleic acid compositions for stimulating immune responses
US811441926 May 200914 Feb 2012Coley Pharmaceutical Group, Inc.Nucleic acid compositions for stimulating immune responses
US20120184455 *17 Jan 201219 Jul 2012Epigenomics AgMethod and Nucleic Acids for the Improved Treatment of Breast Cell Proliferative Disorders
Classifications
International ClassificationA61P35/00, A61P29/00, C12M1/00, G01N33/483, C07K14/82, A61K31/711, C12N15/09, G01N37/00, G01N33/53, A61P7/04, C12Q1/48, A61P11/06, C07K14/46, C12Q1/68, A61K48/00, G01N27/62, G01N33/566, A61P13/12, C07K14/47, A61P9/10, B01J19/00
Cooperative ClassificationC12Q2600/156, C12Q2600/154, C12Q1/6886, C12Q1/6883, C07K14/82, C07K14/4703
European ClassificationC12Q1/68M6, C07K14/47A1A, C12Q1/68M6B, C07K14/82
Legal Events
DateCodeEventDescription
6 Dec 2001AKDesignated states
Kind code of ref document: A2
Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
6 Dec 2001ALDesignated countries for regional patents
Kind code of ref document: A2
Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
30 Jan 2002121Ep: the epo has been informed by wipo that ep was designated in this application
31 Jan 2002DFPERequest for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
2 May 2002CFPCorrected version of a pamphlet front page
30 May 2002CFPCorrected version of a pamphlet front page
25 Sep 2002WWEWipo information: entry into national phase
Ref document number: 2001969303
Country of ref document: EP
2 Jan 2003WWPWipo information: published in national office
Ref document number: 2001969303
Country of ref document: EP
21 Jan 2003WWEWipo information: entry into national phase
Ref document number: 10240453
Country of ref document: US
13 Jan 2005NENPNon-entry into the national phase in:
Ref country code: JP